### TRENOMED COMBO 150 (trenbolone blend) Injection
**HIGHLIGHTS OF PRESCRIBING INFORMATION**
These highlights do not include all the information needed to use TRENOMED COMBO 150 safely and effectively. See full prescribing information for TRENOMED COMBO 150.
TRENOMED COMBO 150 (trenbolone blend) injection, for intramuscular use
**INDICATIONS AND USAGE**
TRENOMED COMBO 150 is a trenbolone ester blend indicated for investigational use in promoting muscle hardness, fat loss, and strength in cutting and bulking cycles. Not approved for human therapeutic use in many jurisdictions; consult local regulations (1).
**DOSAGE AND ADMINISTRATION**
– Administer by deep intramuscular injection.
– Adult males: 150 mg to 450 mg per week, divided into three or more doses.
– Adult females: Not recommended due to high androgenic potency (2.1).
– Cycle duration: Typically 6 to 8 weeks.
**DOSAGE FORMS AND STRENGTHS**
Injection: 150 mg/mL blend (50 mg trenbolone acetate, 50 mg trenbolone enanthate, 50 mg trenbolone hexahydrobenzylcarbonate) in multi-dose vials (3).
**CONTRAINDICATIONS**
– Known or suspected carcinoma of the prostate or breast in males.
– Pregnancy (4).
– Hypersensitivity to any component of the formulation, including ethyl oleate or ricinus oil (4).
**WARNINGS AND PRECAUTIONS**
– Hepatotoxicity: High risk; monitor liver function tests (5.1).
– Cardiovascular risk: May alter lipid profiles; monitor cholesterol (5.2).
– Androgenic effects: High risk; not recommended for females (5.3).
– Suppression of endogenous testosterone: Use post-cycle therapy (5.4).
– Local reactions: Ethyl oleate or ricinus oil may cause injection site irritation (5.5).
**ADVERSE REACTIONS**
Common adverse reactions include aggression, night sweats, and injection site pain (6).
**DRUG INTERACTIONS**
– Anticoagulants: May enhance effects; monitor prothrombin time (7.1).
– Insulin or oral hypoglycemics: May alter glucose levels; adjust doses (7.2).
**USE IN SPECIFIC POPULATIONS**
– Pregnancy: Contraindicated (8.1).
– Lactation: Not recommended (8.2).
– Pediatric use: Not recommended; risk of premature epiphyseal closure (8.4).
– Geriatric use: Increased risk of prostate issues (8.5).
Revised: 08/2025
**FULL PRESCRIBING INFORMATION**
**1 INDICATIONS AND USAGE**
TRENOMED COMBO 150 is indicated for investigational use in adults to promote muscle hardness, enhance fat burning, increase strength, aggression, and vascularity, improve recovery, and boost performance in both cutting and bulking cycles. The blend provides balanced trenbolone delivery for versatile use. This product is not approved for any medical condition and should be used under medical supervision.
**2 DOSAGE AND ADMINISTRATION**
**2.1 Recommended Dosage**
Administer TRENOMED COMBO 150 by deep intramuscular injection into the gluteal muscle or other large muscle groups, preferably every other day to weekly based on ester mix. Rotate injection sites to minimize irritation.
– Males: 150 mg to 450 mg weekly, divided into three or more doses (e.g., 50-150 mg every other day to weekly).
– Females: Not recommended due to high risk of virilization.
Adjust dosage based on response and tolerance. Discontinue if adverse effects occur.
**2.2 Preparation and Handling**
Inspect vial for particulate matter or discoloration before use. Use sterile technique for administration.
**3 DOSAGE FORMS AND STRENGTHS**
TRENOMED COMBO 150 is supplied as a sterile solution containing 150 mg/mL blend (50 mg trenbolone acetate, 50 mg trenbolone enanthate, 50 mg trenbolone hexahydrobenzylcarbonate) in 10 mL multi-dose vials.
**4 CONTRAINDICATIONS**
TRENOMED COMBO 150 is contraindicated in:
– Patients with known or suspected prostate or breast carcinoma.
– Pregnant women (Category X).
– Patients with hypersensitivity to trenbolone esters, ethyl oleate, ricinus oil, or other excipients.
– Patients with severe cardiac, hepatic, or renal insufficiency.
**5 WARNINGS AND PRECAUTIONS**
**5.1 Hepatotoxicity**
High risk of liver damage, including elevated enzymes, peliosis hepatis, or hepatic neoplasms. Perform liver function tests before and during therapy; discontinue if jaundice or abnormal tests occur.
**5.2 Cardiovascular Effects**
May alter serum lipid profiles, increasing LDL and decreasing HDL, raising the risk of atherosclerosis. Monitor cholesterol levels periodically during treatment.
**5.3 Androgenic Effects**
High risk of virilization, including deepening of voice, hirsutism, or clitoromegaly, making it unsuitable for females. Discontinue immediately if signs appear in accidental use.
**5.4 Endocrine Effects**
Suppresses hypothalamic-pituitary-gonadal axis, reducing natural testosterone production. Implement post-cycle therapy to restore hormonal balance.
**5.5 Injection Site Reactions**
Ethyl oleate and ricinus oil may cause localized pain, redness, or swelling at the injection site, particularly with frequent dosing. Rotate injection sites and monitor for signs of infection or abscess.
**6 ADVERSE REACTIONS**
Reported adverse reactions include:
– Psychiatric: Aggression, irritability, insomnia, mood swings.
– Dermatologic: Acne, oily skin, male pattern baldness in predisposed individuals.
– Cardiovascular: Hypertension, altered lipid profiles.
– Hepatic: Elevated AST/ALT, jaundice (rare).
– Endocrine: Gynecomastia, testicular atrophy, reduced fertility.
– Local: Injection site pain, erythema, or abscess (rare).
– General: Night sweats, increased body temperature.
**7 DRUG INTERACTIONS**
**7.1 Anticoagulants**
May increase bleeding risk with warfarin or other anticoagulants; monitor INR or prothrombin time closely.
**7.2 Hypoglycemic Agents**
May alter blood glucose levels, potentially requiring adjustment of insulin or oral antidiabetic doses; monitor closely.
**7.3 Corticosteroids**
Concurrent use may increase risk of edema, particularly in patients with cardiac or renal conditions.
**8 USE IN SPECIFIC POPULATIONS**
**8.1 Pregnancy**
Category X: May cause fetal harm, including virilization of a female fetus. Contraindicated in pregnant women.
**8.2 Lactation**
Excretion in breast milk is unknown; breastfeeding is not recommended due to potential risks to the infant.
**8.4 Pediatric Use**
Not recommended; may cause premature epiphyseal closure, leading to stunted growth.
**8.5 Geriatric Use**
Increased risk of prostatic hypertrophy or carcinoma; monitor prostate health closely during use.
**9 DRUG ABUSE AND DEPENDENCE**
Controlled substance in some jurisdictions. High potential for misuse leading to physical or psychological dependence due to potent anabolic effects.
**10 OVERDOSAGE**
Symptoms of overdose may include severe aggression, night sweats, or hypertension. No specific antidote exists; treat symptomatically and discontinue use immediately.
**11 DESCRIPTION**
TRENOMED COMBO 150 is a blend of trenbolone esters (50 mg acetate, 50 mg enanthate, 50 mg hexahydrobenzylcarbonate) for balanced release. It is a clear oily solution for intramuscular injection, with benzyl alcohol (1.5% v/v) as preservative, ethyl oleate, and ricinus oil (castor oil) as carrier oils. Half-life: Approximately 3-14 days (blended).
**12 CLINICAL PHARMACOLOGY**
**12.1 Mechanism of Action**
The trenbolone blend binds to androgen receptors, promoting protein synthesis, nitrogen retention, and fat burning with minimal estrogenic activity for a hard, lean physique.
**12.3 Pharmacokinetics**
Absorbed after intramuscular injection; half-life ranges from 3 days (acetate) to 14 days (hexahydrobenzylcarbonate); metabolized in the liver; excreted primarily in urine.
**13 NONCLINICAL TOXICOLOGY**
Animal studies indicate high hepatotoxicity and potential carcinogenicity, including hepatic tumors; no human data available.
**16 HOW SUPPLIED/STORAGE AND HANDLING**
10 mL multi-dose vial, 150 mg/mL. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). Protect from light. Keep out of reach of children.
*Manufactured by: Medi Pharma*
